KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

West Pharmaceutical Services (WST) Accumulated Depreciation & Amortization (2016 - 2026)

West Pharmaceutical Services has reported Accumulated Depreciation & Amortization over the past 18 years, most recently at $45.2 million for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 13.0% to $45.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $45.2 million through Mar 2026, up 13.0% year-over-year, with the annual reading at $171.4 million for FY2025, 10.3% up from the prior year.
  • Accumulated Depreciation & Amortization was $45.2 million for Q1 2026 at West Pharmaceutical Services, down from $171.4 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $1.3 billion in Q3 2023 and troughed at $35.6 million in Q1 2024.
  • The 5-year median for Accumulated Depreciation & Amortization is $137.3 million (2023), against an average of $490.0 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 97.18% in 2024 and later surged 209.45% in 2025.
  • Tracing WST's Accumulated Depreciation & Amortization over 5 years: stood at $120.6 million in 2022, then grew by 13.85% to $137.3 million in 2023, then rose by 13.18% to $155.4 million in 2024, then grew by 10.3% to $171.4 million in 2025, then plummeted by 73.63% to $45.2 million in 2026.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $45.2 million, $171.4 million, and $124.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.